Insulet (PODD) Receives Coverage Optimism Score of 0.12

Headlines about Insulet (NASDAQ:PODD) have been trending somewhat positive recently, according to Accern Sentiment. The research group scores the sentiment of press coverage by reviewing more than 20 million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Insulet earned a daily sentiment score of 0.12 on Accern’s scale. Accern also gave media headlines about the medical instruments supplier an impact score of 45.8053969295982 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.

Insulet (NASDAQ:PODD) opened at $68.49 on Friday. The company has a debt-to-equity ratio of 4.65, a current ratio of 4.88 and a quick ratio of 4.42. The stock has a market capitalization of $4,014.96, a PE ratio of -136.98 and a beta of 1.58. Insulet has a 52 week low of $36.80 and a 52 week high of $72.99.

Insulet (NASDAQ:PODD) last posted its earnings results on Thursday, November 2nd. The medical instruments supplier reported ($0.04) earnings per share for the quarter, topping the consensus estimate of ($0.10) by $0.06. The firm had revenue of $121.80 million during the quarter, compared to analysts’ expectations of $114.02 million. Insulet had a negative return on equity of 43.85% and a negative net margin of 6.66%. The firm’s revenue was up 28.4% compared to the same quarter last year. During the same quarter in the previous year, the business earned ($0.05) earnings per share. sell-side analysts expect that Insulet will post -0.43 earnings per share for the current fiscal year.

A number of equities analysts recently commented on PODD shares. Canaccord Genuity upgraded Insulet from a “hold” rating to a “buy” rating and raised their target price for the company from $50.00 to $65.00 in a report on Wednesday, November 1st. Robert W. Baird set a $65.00 price objective on Insulet and gave the company a “buy” rating in a research note on Friday, October 13th. Jefferies Group lifted their price objective on Insulet from $58.00 to $67.00 and gave the company a “buy” rating in a research note on Friday, November 3rd. Wedbush reiterated a “buy” rating and issued a $65.00 price objective (up previously from $60.00) on shares of Insulet in a research note on Tuesday, October 10th. Finally, Barclays reiterated a “buy” rating and issued a $78.00 price objective on shares of Insulet in a research note on Wednesday, December 13th. Eight research analysts have rated the stock with a hold rating and ten have issued a buy rating to the company. The stock has a consensus rating of “Buy” and a consensus price target of $61.29.

In other Insulet news, Director James C. Mullen bought 2,500 shares of the firm’s stock in a transaction that occurred on Monday, November 13th. The stock was purchased at an average price of $67.45 per share, for a total transaction of $168,625.00. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 1.90% of the stock is owned by insiders.

WARNING: This article was first reported by Ticker Report and is the property of of Ticker Report. If you are viewing this article on another domain, it was copied illegally and reposted in violation of U.S. and international trademark & copyright laws. The legal version of this article can be accessed at https://www.tickerreport.com/banking-finance/3126207/insulet-podd-receives-coverage-optimism-score-of-0-12.html.

About Insulet

Insulet Corporation is engaged in the development, manufacturing and sale of the OmniPod Insulin Management System (the OmniPod System), an insulin delivery system for people with insulin-dependent diabetes. The Omnipod System features a self-adhesive disposable tubeless Omnipod device, which is worn on the body for approximately three days at a time and its wireless companion, the handheld Personal Diabetes Manager (PDM).

Insider Buying and Selling by Quarter for Insulet (NASDAQ:PODD)

Receive News & Ratings for Insulet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insulet and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

How to Trade on Forex – 8 Steps for Beginners
How to Trade on Forex – 8 Steps for Beginners
Super Nintendo World Theme Park Officially Starts Construction
Super Nintendo World Theme Park Officially Starts Construction
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Camera Zooms In and Can Recognize Faces
Camera Zooms In and Can Recognize Faces
Netflix Could See 150 Million Worldwide Subscribers
Netflix Could See 150 Million Worldwide Subscribers
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back


Leave a Reply

© 2006-2018 Ticker Report. Google+.